CNBC International · Oct 17, 2026
With Dimitris Moulavasilis, Group CEO of M42
M42 has sequenced more than 950,000 genomes for the Emirati Genome Program, Dimitris Moulavasilis, Group CEO of the Abu Dhabi health company M42, told CNBC International.
Most health systems act once a patient is already sick. Dimitris wants M42 to use genomics, digital health and AI to predict and prevent disease instead, and to sell that model to other countries.
"The big problem in healthcare today is that it's fragmented, episodic and reactive. We act only when the patient gets sick." — Dimitris Moulavasilis
Dimitris ran M42's global patient-care platform before taking over as CEO in May 2025. The company runs more than 480 facilities in 27 countries and serves about 15 million patients a year, according to the video's description.
The full segment is covered here so you can skip it.
Here are the 6 insights that matter.
Key Takeaways
M42 has sequenced more than 950,000 genomes at 30x depth for the Emirati Genome Program
90% of global genomic datasets cover 10% of the world's population, Dimitris says, which is why the UAE built its own
Premarital screening could cut inheritable disorders by up to 75% within one generation, in M42's ambition
A biobank used only for storage is "an expensive freezer", Dimitris says; it pays for itself only by feeding research and care
Patients own their genomic data, and a genome should never be a commercial asset, in Dimitris's view
M42 acquires about 25 clinics a year, and its business is already split 50/50 between the UAE and abroad
1. Healthcare Acts Too Late
M42 was formed in 2023 by merging G42 Healthcare's AI and data expertise with Mubadala Health's clinical network. In 2025 it reorganized into four segments: global patient care, integrated health solutions, digital health solutions and AI life sciences.
Dimitris Moulavasilis says M42 was built to connect four capabilities that health systems keep separate
"What if we connect advanced specialty care, genomics capability, digital health, and artificial intelligence to solve this problem." — Dimitris Moulavasilis
The goal of joining them, in his account, is prediction, prevention and personalization. Care today, he said, starts only once a patient is already ill.
